Double-Dose hope for devastating brain cancer spread

This early-stage trial is testing a new way to give an immunotherapy drug called nivolumab to patients with melanoma or lung cancer that has spread to the membranes surrounding the brain and spinal cord. The goal is to see if giving the drug directly into the spinal fluid, along with the standard IV infusion, is safe and what dose works best. Researchers hope this two-part approach helps the immune system better attack cancer cells in this hard-to-treat area.